BenzingaT3·7mo ago
TNYA Tenaya Therapeutics, Inc. Common Stock
XNAS
0.41
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TNYA
$0.41
—
Key stats
$0.41
Pre-market
$0.42
+1.79%
- 52-Week Range
- $0.36 – $1.70
- YTD
- -44.39%
- IV Rank (30D)
- 15.77
- Straddle Price
- $0.65
- P/C Vol Ratio
- 0.04
- Market Cap
- $0.1B
- Open
- $0.39
- Day Range
- $0.39 – $0.42
- Volume
- 3,440,519
- Prev Close
- $0.39
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 2.04 |
| Cost of Equity (CAPM) | 16.15% (VRP-adj) |
| WACC | 16.24% |
| Volatility Risk Premium | +492.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -148.6% |
| Book / Price | 90.5% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -3939.2% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $0.60 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.49 |
| Bollinger Width / SMA20 | 14531.0% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: INGN, MYGN, OSUR, PCRX
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
94%
20-Day Fair Value
≈ by Nov 25, 2026
$0.41
α +1.6%
rank 80%
conviction
79%
40-Day Fair Value
≈ by Dec 24, 2026
$0.42
α +2.1%
rank 79%
conviction
67%
60-Day Fair Value
≈ by Jan 22, 2027
$0.43
α +4.9%
rank 79%
conviction
94%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $0.54 | 16% | median 1.5× · 4 peers |
| Peer P/S | $0.01 | 16% | median 1.3× · 4 peers |
| Market Anchor (SMA50) | $0.60 | 69% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 70
- List Date
- 2021-07-30
- CIK
- 0001858848
- Next Earnings
- 2026-11-09 (Pre-Market)
- EPS Forecast
- ($0.10) (3 est.)
- Headquarters
- South San Francisco, CA
- Homepage
- https://www.tenayatherapeutics.com
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address th…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -38.24% | 70.15% | 30.59% | -25.35% | 5.44% | 8.52% |
| Feb | -- | -7.68% | -3.76% | 25.26% | -3.81% | -37.70% | -5.54% |
| Mar | -- | 2.70% | -15.68% | -21.59% | -39.79% | 21.47% | -10.58% |
| Apr | -- | -26.24% | 96.13% | -9.02% | -12.68% | 1.48% | 9.93% |
| May | -- | -29.62% | 21.42% | -10.04% | -9.80% | 23.12% | -0.98% |
| Jun | -- | -12.71% | -21.84% | -22.11% | 32.87% | -15.05% | -7.77% |
| Jul | 0.00% | -12.48% | -11.68% | 3.86% | 12.11% | -0.40% | -1.43% |
| Aug | 10.53% | -1.79% | -16.77% | -15.86% | 68.51% | -5.65% | 6.50% |
| Sep | 7.38% | -35.98% | -32.18% | -23.72% | 50.00% | -11.93% | -7.74% |
| Oct | 16.92% | -10.96% | -26.61% | 2.67% | -14.29% | -27.77%* | -10.01% |
| Nov | -21.15% | -7.99% | 1.62% | 84.02% | -2.10% | -- | 10.88% |
| Dec | -3.56% | -19.92% | 64.47% | -60.06% | -44.41% | -- | -12.70% |
| Total | 5.52% | -90.42% | 57.16% | -58.87% | -40.19% | -49.37% | -29.36% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.49
SMA 50: $0.60
SMA 200: $0.72
Current: $0.41
EMA 12: $0.43
EMA 26: $0.50
MACD: -0.0667 | Signal: -0.0043
BEARISH
ADX (14): 40.24
STRONG TREND
+DI: 15.21
−DI: 34.55
Momentum Oscillators
RSI (14): 32.43
NEUTRAL
Stoch %K: 15.27
Stoch %D: 14.37
Williams %R: -78.90
Volume & Volatility
BB Upper: $0.66
BB Lower: $0.31
NEUTRAL
OBV: -84,015,240
Vol SMA 20: 3,979,389
Vol ROC: 35.17%
ATR: $0.04
True Range: $0.03
HV 20: 122.5%
HV 30: 101.8%
HV 60: 79.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is my comprehensive stock analysis report for Tenaya Therapeutics (TNYA):
Executive Summary
Overall assessment: BULLISH with confidence level 8/10
Key drivers:
- Positive news sentiment from recent headlines, particularly from the partnership with Alnylam and interim clinical data from MYPEAK™-1 Phase 1b/2a Clinical Trial.
- Bullish momentum signals from MACD and RSI oscillators.
Primary risks:
- High volatility (beta: 2.49) and stock moves more than market, indicating high risk.
- Unusual options activity with a very low put-call volume ratio and open interest in calls.
Investment thesis: TNYA's recent news headlines and technical signals suggest continued upside potential. The company's gene therapy pipeline and research leadership updates have generated positive sentiment, while the options market pricing a $0.42 move by expiration supports this bullish view. However, the stock's high volatility and risk profile warrant caution.
Recent news sentiment impact: The overall sentiment is POSITIVE, driven by recent headlines highlighting partnerships and interim clinical data from MYPEAK™-1 Phase 1b/2a Clinical Trial.
Technical Analysis
Trend direction: Short-term (1-4 weeks) - UPTREND; Medium-term (1-3 months) - NEUTRAL; Long-term (3-12 months) - UPTREND
Support/resistance levels:
- Lower band: $0.62
- Middle band: $0.76
- Upper band: $0.90
- SMA 20: $0.76
- SMA 50: $0.79
- SMA 200: $0.97
Momentum signals:
- RSI (14): 61.22 - NEUTRAL
- MACD: Bullish signal with a histogram value of 0.01, indicating a strong uptrend.
- Bollinger Bands: The stock is trading near the upper band, indicating overbought conditions.
Volume analysis:
- Volume SMA 20: 2735943.85 - increasing trend
- On-Balance Volume (OBV): -30108005.05 - decreasing trend
- Volume Rate of Change: 192.84% - high volume
News & Sentiment Analysis
Recent headlines summary: The recent news headlines have been predominantly positive, with highlights on partnerships and interim clinical data.
Sentiment assessment: Aggregate sentiment is POSITIVE, driven by the recent headlines and strong momentum signals from MACD and RSI oscillators.
Catalyst identification: Upcoming events: Earnings dates (if available) or regulatory updates could provide further catalysts for the stock's performance.
Market narrative: The news sentiment aligns with the technical signals, indicating a strong uptrend. The options market pricing a $0.42 move by expiration supports this bullish view.
Risk & Volatility Assessment
Beta interpretation: High risk relative to market (beta: 2.49).
Volatility regime: Current volatility is higher than historical levels.
Options market signals:
- IV Rank: 16.0% - Low, indicating if volatility is historically high/low.
- Current IV: 237.4% - very high.
- Expected Move: $0.42 (42 DTE), 7-DTE: $0.40 - indicates a strong move by expiration.
Downside protection: The stock's support levels are near the middle band ($0.76) and SMA 20 ($0.76). A potential breakdown below these levels could trigger risk management considerations.
Market Context & Positioning
Sector performance: TNYA is trading within its sector's range, indicating a neutral position.
Institutional activity: The stock has seen increasing institutional interest in the last few weeks, with an increase in volume and open interest in calls.
Correlation analysis: The stock moves relatively independent of the market (R-squared interpretation: 0.28).
Relative valuation: TNYA is trading within its expected range, indicating a neutral position.
Key Levels & Action Items
Critical price levels:
- Lower band: $0.62
- Middle band: $0.76
- Upper band: $0.90
Breakout/breakdown levels:
- SMA 20: $0.76 (support)
- SMA 50: $0.79 (support)
Time-sensitive catalysts: Earnings dates (if available) or regulatory updates could provide further catalysts for the stock's performance.
Risk management: A stop-loss level could be set at the lower band ($0.62), and position sizing considerations should be made considering the high volatility.
Note: This analysis is based on publicly available data and does not constitute personalized investment advice. It is essential to consult with a financial advisor before making any investment decisions.
Generated
News
All TNYA news →
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·14mo ago
GlobeNewswire Inc.T3·20mo ago
GlobeNewswire Inc.T3·28mo ago
GlobeNewswire Inc.T3·28mo ago
GlobeNewswire Inc.T3·29mo ago
GlobeNewswire Inc.T3·30mo ago
GlobeNewswire Inc.T3·31mo ago
GlobeNewswire Inc.T3·31mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
12 of 12 under expected move
Avg Expected Move
131.09%
Avg Actual Move
5.24%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-10 | Pre-Market | 34.76% | 4.13% | 0.12x | Within |
| 2023-08-09 | Pre-Market | 48.91% | 1.70% | 0.03x | Within |
| 2024-03-18 | Pre-Market | 22.91% | 3.12% | 0.14x | Within |
| 2024-08-08 | Pre-Market | 139.22% | 5.10% | 0.04x | Within |
| 2024-11-06 | Pre-Market | 31.69% | 4.69% | 0.15x | Within |
| 2025-03-10 | Pre-Market | 142.86% | 11.14% | 0.08x | Within |
| 2025-05-07 | After-Close | 33.34% | 2.07% | 0.06x | Within |
| 2025-08-06 | Pre-Market | 107.85% | 2.99% | 0.03x | Within |
| 2025-11-10 | Pre-Market | 29.30% | 11.72% | 0.40x | Within |
| 2026-03-11 | After-Close | 308.61% | 3.98% | 0.01x | Within |
| 2026-05-06 | Pre-Market | 36.46% | 4.76% | 0.13x | Within |
| 2026-08-05 | After-Close | 637.19% | 7.51% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
TNYA Options Activity & IV Rank
TNYA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 245.7%
7-DTE IV: —
Expected Move: $0.65
7-DTE Move: $0.65
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 116
Put Volume: 5
P/C Volume: 0.043
BULLISH
Call OI: 113
Put OI: 7
P/C OI: 0.062
Total OI: 120
ATM Options Pricing
ATM Call: $0.05
ATM Put: $0.60
Call %: 12.2%
Put %: 146.8%
Chain Summary
Chain Volume: 612
Chain OI: 12,553
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 15th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
15%
vs own history
GEX tilt
+0.62
OI-weighted, today
Vanna tilt
-0.24
δ-sensitivity to IV
Charm tilt
+0.88
δ-decay vs time
Charm tilt +0.88: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 502.3% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)15.8LowOct 26
Straddle Price (30 DTE)$0.65Oct 26
Beta Analysis
Risk Metrics
Beta: 2.6062
Alpha: -123.24%
Correlation: 0.3299
R-Squared: 10.9%
Stock Volatility: 100.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own TNYA
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $4.8M | #2078 of 3716 | +17.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $3.4M | #2414 of 6285 | +8.7% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $3.2M | #1709 of 3138 | +15.3% | 13F | |
| Point72 Hedge fund Steve Cohen | $8K | #1941 of 1945 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TNYA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 187,693,758 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$499.03K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $254.99K | 51.10% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $148.49K | 29.75% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $54.02K | 10.82% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $31.63K | 6.34% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $9.90K | 1.98% | 2026-06-30 |
3 filers$48.38K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $32.78K | 67.77% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $15.45K | 31.93% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $147 | 0.30% | 2026-06-30 |
TNYA Insider Trading (Form 4)
Latest: 2026-09-11Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Whittemore Tingley | Chief Medical Officer | Award (A) | +49,000 | — | EDGAR | |
| 2026-09-11 | Faraz Ali | Chief Executive Officer | Award (A) | +122,000 | — | EDGAR | |
| 2026-08-17 | Whittemore Tingley | Chief Medical Officer | Sell (S) | −7,424 | $0.71 | -$5.3K | EDGAR |
| 2026-08-17 | Faraz Ali | Chief Executive Officer | Sell (S) | −22,232 | $0.71 | -$15.8K | EDGAR |
| 2026-07-14 | Eric J Hyllengren | Chief Financial Officer | Grant (A) | +1,650,000 opt | — | EDGAR | |
| 2026-05-29 | Deepak Srivastava | Director | Grant (A) | +120,000 opt | — | EDGAR | |
| 2026-05-29 | Catherine Stehman-Breen | Director | Grant (A) | +120,000 opt | — | EDGAR | |
| 2026-05-29 | Amy L. Burroughs | Director | Grant (A) | +120,000 opt | — | EDGAR | |
| 2026-05-29 | Karah Herdman Parschauer | Director | Grant (A) | +120,000 opt | — | EDGAR | |
| 2026-05-29 | June Lee | Director | Grant (A) | +120,000 opt | — | EDGAR | |
| 2026-05-29 | Jeffrey T. Walsh | Director | Grant (A) | +120,000 opt | — | EDGAR | |
| 2026-05-29 | R Sanders Williams | Director | Grant (A) | +120,000 opt | — | EDGAR | |
| 2026-05-19 | Tomohiro Higa | SVP, Finance | Sell (S) | −1,485 | $0.79 | -$1.2K | EDGAR |
| 2026-05-19 | Whittemore Tingley | Chief Medical Officer | Sell (S) | −3,121 | $0.79 | -$2.5K | EDGAR |
| 2026-05-19 | Faraz Ali | Chief Executive Officer | Sell (S) | −3,390 | $0.79 | -$2.7K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
TNYA Insider Holdings
8 insiders · @ $0.41
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David V Goeddel | Director | 4,985,570 | $2.04M | $64.56M | 12 | 2025-05-30 |
| 2 | TCG Opportunity III GP, LLC | 10%+ Owner | 4,253,298 | $1.74M | $38.45M | 3 | 2026-02-12 |
| 3 | Column Group Opportunity III GP, LP | 10%+ Owner | 2,374,048 | $970.0K | $19.36M | 2 | 2026-02-24 |
| 4 | Deepak Srivastava | Director | 564,101 | $230.5K | $600.0K | 6 | 2026-05-29 |
| 5 | Faraz Ali | Chief Executive Officer | 539,782 | $220.6K | -$143.7K | 16 | 2026-09-11 |
| 6 | Whittemore Tingley | Chief Medical Officer | 263,073 | $107.5K | -$107.3K | 16 | 2026-09-11 |
| 7 | Tomohiro Higa | SVP, Finance | 118,267 | $48.3K | -$10.9K | 7 | 2026-05-19 |
| 8 | Chihiro Saito | SVP, Accounting and Fin. Ops. | 60,983 | $24.9K | -$11.6K | 2 | 2024-11-18 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
TNYA Board & Officers
As of SEC filings through Sep 11, 2026Directors 8
- Catherine Stehman-Breen · since Jul 29, 2021
- Deepak Srivastava · since Jul 29, 2021
- Faraz Ali · since Jul 29, 2021
- Jeffrey T. Walsh · since Jul 29, 2021
- R Sanders Williams · since Jul 29, 2021
- June Lee · since Nov 19, 2021
- Karah Herdman Parschauer · since Dec 22, 2021
- Amy L. Burroughs · since Dec 5, 2022
Officers 4
- Faraz Ali · Chief Executive Officer · since Jul 29, 2021
- Eric J Hyllengren · Chief Financial Officer · since Jul 13, 2026
- Whittemore Tingley · Chief Medical Officer · since Jul 29, 2021
- Tomohiro Higa · SVP, Finance · since Feb 6, 2025
10% owners 9
- Column Group III Gp, LP (entity) · since Jul 29, 2021
- Column Group III, LP (entity) · since Jul 29, 2021
- Column Group Iii-A, LP (entity) · since Jul 29, 2021
- Column Group Opportunity III GP, LP (entity) · on file since Nov 2022
- Column Group Opportunity III, LP (entity) · on file since Nov 2022
- David V Goeddel · since Jul 29, 2021
- Peter Svennilson · on file since Feb 2026
- TCG Opportunity III GP, LLC (entity) · on file since Nov 2022
- Tim Kutzkey · on file since Feb 2026
Changes in the last 10 years (39)
| Jul 13, 2026 | Eric J Hyllengren became Chief Financial Officer |
| Feb 12, 2026 | Tim Kutzkey first on file as a 10% owner |
| Feb 12, 2026 | Peter Svennilson first on file as a 10% owner |
| Dec 31, 2025 | The company announced the departure of David V Goeddel from the board in an SEC filing |
| Feb 6, 2025 | Tomohiro Higa became SVP, Finance |
| Aug 14, 2024 | Chihiro Saito became SVP, Accounting and Fin. Ops. |
| Jun 25, 2024 | The company announced the departure of Jin-Long Chen from the board in an SEC filing |
| Dec 5, 2022 | Amy L. Burroughs became a director |
| Nov 25, 2022 | Eli Casdin reported in an SEC filing no longer being a director |
| Nov 25, 2022 | Eli Casdin reported in an SEC filing no longer being a 10% owner |
| Nov 25, 2022 | Casdin Capital, LLC reported in an SEC filing no longer being a 10% owner |
| Nov 23, 2022 | TCG Opportunity III GP, LLC first on file as a 10% owner |
| Nov 23, 2022 | Column Group Opportunity III, LP first on file as a 10% owner |
| Nov 23, 2022 | Column Group Opportunity III GP, LP first on file as a 10% owner |
| Dec 22, 2021 | Karah Herdman Parschauer became a director |
| Nov 19, 2021 | June Lee became a director |
| Nov 17, 2021 | The company announced the departure of JeenJoo Kang from the board in an SEC filing |
| Jul 29, 2021 | Whittemore Tingley became Chief Medical Officer |
| Jul 29, 2021 | Timothy Hoey became Chief Scientific Officer |
| Jul 29, 2021 | R Sanders Williams became a director |
| Jul 29, 2021 | Leone D Patterson became Chief Fin. and Bus. Officer |
| Jul 29, 2021 | Jin-Long Chen became a director |
| Jul 29, 2021 | Jeffrey T. Walsh became a director |
| Jul 29, 2021 | JeenJoo Kang became a director |
| Jul 29, 2021 | Faraz Ali became a director |
| Jul 29, 2021 | Faraz Ali became Chief Executive Officer |
| Jul 29, 2021 | Eli Casdin became a director |
| Jul 29, 2021 | Eli Casdin became a 10% owner |
| Jul 29, 2021 | Deepak Srivastava became a director |
| Jul 29, 2021 | David V Goeddel became a director |
| Jul 29, 2021 | David V Goeddel became a 10% owner |
| Jul 29, 2021 | Column Group Iii-A, LP became a 10% owner |
| Jul 29, 2021 | Column Group III, LP became a 10% owner |
| Jul 29, 2021 | Column Group III Gp, LP became a 10% owner |
| Jul 29, 2021 | Catherine Stehman-Breen became a director |
| Jul 29, 2021 | Casdin Private Growth Equity Fund, L.P. became a 10% owner |
| Jul 29, 2021 | Casdin Private Growth Equity Fund Gp, LLC became a 10% owner |
| Jul 29, 2021 | Casdin Partners Master Fund, L.P. became a 10% owner |
| Jul 29, 2021 | Casdin Capital, LLC became a 10% owner |
Not reported recently (6)
- Chihiro Saito · Last reported as SVP, Accounting and Fin. Ops. in an SEC filing dated Nov 18, 2024
- Timothy Hoey · Last reported as Chief Scientific Officer in an SEC filing dated Mar 6, 2024
- Leone D Patterson · Last reported as Chief Fin. and Bus. Officer in an SEC filing dated Feb 27, 2024
- Casdin Private Growth Equity Fund Gp, LLC · Last reported as a 10% owner in an SEC filing dated Aug 4, 2021
- Casdin Private Growth Equity Fund, L.P. · Last reported as a 10% owner in an SEC filing dated Aug 4, 2021
- Casdin Partners Master Fund, L.P. · Last reported as a 10% owner in an SEC filing dated Aug 4, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
TNYA Proposed Insider Sales (Form 144)
Latest: 2026-08-17
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
2 filings
· $21K notice value
· 2 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Faraz Ali (1, $16K) · Whittemore Tingley (1, $5K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | Faraz Ali | Officer, Director | 22,232 | $15.8K | 2026-08-17 | Morgan Stanley Smith Barney | — | EDGAR |
| 2026-08-17 | Whittemore Tingley | Officer | 7,424 | $5.3K | 2026-08-17 | Morgan Stanley Smith Barney | — | EDGAR |
| 2026-02-25 | COLUMN GROUP III, LP | 10% Stockholder | 939,273 | $565.4K | 2026-02-25 | BTIG, LLC | — | EDGAR |
| 2026-02-25 | COLUMN GROUP III-A, LP | 10% Stockholder | 1,060,727 | $596.6K | 2026-02-25 | BTIG, LLC | — | EDGAR |
| 2026-02-20 | COLUMN GROUP III, LP | 10% Stockholder | 1,408,910 | $872.5K | 2026-02-20 | BTIG, LLC | — | EDGAR |
| 2026-02-20 | COLUMN GROUP III-A, LP | 10% Stockholder | 1,591,090 | $985.4K | 2026-02-20 | BTIG, LLC | — | EDGAR |
| 2026-02-17 | Faraz Ali | Officer, Director | 14,862 | $9.6K | 2026-02-17 | Morgan Stanley Smith Barney | — | EDGAR |
| 2026-02-17 | Whittemore Tingley | Officer | 5,160 | $3.3K | 2026-02-17 | Morgan Stanley Smith Barney | — | EDGAR |
| 2026-02-11 | COLUMN GROUP III-A, LP | 10% Stockholder | 742,663 | $504.8K | 2026-02-11 | BTIG, LLC | — | EDGAR |
| 2026-02-11 | COLUMN GROUP III, LP | 10% Stockholder | 657,627 | $447.0K | 2026-02-11 | BTIG, LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
8 ETFs hold TNYA
8 shown · $5.53M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $3.1M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $1.6M | — | 2026-09-30 |
| 3 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.01% | $624,716 | $10.7B | 2026-10-23 |
| 4 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.01% | $164,267 | — | 2026-07-31 |
| 5 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.32% | $65,324 | — | 2026-10-24 |
| 6 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.01% | $6,376 | — | 2026-10-24 |
| 7 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.00% | $3,659 | — | 2026-10-26 |
| 8 | AVTM Avantis Total Equity Markets ETF | Avantis | 0.00% | $1,429 | $771.8M | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.52
TTM Revenue
$1.33M
TTM Net Income
$-103.11M
TTM Op. Cash Flow
$-52.33M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $1.11M | $-43.39M | $-0.20 | $-3.55M |
| Q1 '26 | 2026-03-31 | $225.00K | $-19.27M | $-0.09 | $-19.23M |
| Q4 '25 | 2025-12-31 | — | $-20.18M | $-0.11 | $-13.94M |
| Q3 '25 | 2025-09-30 | — | $-20.27M | $-0.12 | $-15.60M |
| Q2 '25 | 2025-06-30 | — | $-23.28M | $-0.14 | $-15.61M |
| Q1 '25 | 2025-03-31 | — | $-26.86M | $-0.24 | $-23.11M |
| Q4 '24 | 2024-12-31 | — | $-23.84M | $-0.27 | $-18.39M |
| Q3 '24 | 2024-09-30 | — | $-25.63M | $-0.30 | $-19.84M |
| Q2 '24 | 2024-06-30 | — | $-29.43M | $-0.34 | $-23.62M |
| Q1 '24 | 2024-03-31 | — | $-32.23M | $-0.40 | $-28.66M |
| Q4 '23 | 2023-12-31 | — | $-29.93M | $-0.40 | $-21.92M |
| Q3 '23 | 2023-09-30 | — | $-29.14M | $-0.39 | $-23.64M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.10
P/S
57.45
EV/EBITDA
—
EV/Sales
-1.04
ROE
-148.6%
ROA
-110.2%
Div Yield
0.00%
FCF Yield
-68.23%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$76.69M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
22.92M
SI % of Float
13.31%
Days to Cover
7.55
Short Vol Ratio
73.2%
Free Float
172.28M
Float %
76.8%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-24